Tags

Type your tag names separated by a space and hit enter

Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT.
Bone Marrow Transplant. 2020 May 15 [Online ahead of print]BM

Abstract

Indications for autologous (auto-HCT) and allogeneic transplantation (allo-HCT) in relapsed/refractory Hodgkin lymphoma (rrHL) have been long established. The expectation is that long-term outcomes have significantly improved over time with increased experience in these procedures. The objective of this study was to assess whether this is the case and to identify further areas of improvement. A total of 13,639 adult patients receiving an auto-HCT or allo-HCT for rrHL were reported to the European Society for Blood and Marrow Transplantation (EBMT) over a 25-year period. Regarding auto-HCT, recipients are younger, interval between diagnosis and transplant shorter, peripheral blood has become the universal stem cell source and the use of total body irradiation is almost non-existent in recent years. Allo-HCT is currently mostly used as a second transplant; recipients are younger, fitter and less frequently, chemorefractory. Reduced intensity conditioning protocols have vastly replaced myeloablative protocols. Increasing numbers of haplo-HCT have been reported. Both in auto-HCT and allo-HCT, NRM, PFS and OS have significantly improved but relapse remains the main cause of treatment failure. A better selection of patients and improvements in the supportive care has resulted in a reduction in the NRM. Relapse after HCT remains unchanged and further research is needed.

Authors+Show Affiliations

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain. asureda@iconcologia.net.University Hematology Clinic, Medical faculty, Skopje, Republic of North Macedonia.EBMT, Lymphoma Working party, Paris, France.EBMT, Lymphoma Working party, Paris, France.EBMT, Lymphoma Working party, Paris, France.Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.Department of Clinical Haematology, AP-HP, Necker Hospital, Paris, France.Department of Hematology, University College London Hospital, London, UK.Bone Marrow Transplant Unit, University Hospital Bristol, Bristol, UK.Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.Department of Hematology, Academische Ziekenhuis, Maastricht, Netherlands.Department of Stem Cell Transplantation, Fundeni Clinical Institute, Bucharest, Romania.Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32415225

Citation

Sureda, Anna, et al. "Changes in Patients Population and Characteristics of Hematopoietic Stem Cell Transplantation for Relapsed/refractory Hodgkin Lymphoma: an Analysis of the Lymphoma Working Party of the EBMT." Bone Marrow Transplantation, 2020.
Sureda A, Genadieva Stavrik S, Boumendil A, et al. Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. Bone Marrow Transplant. 2020.
Sureda, A., Genadieva Stavrik, S., Boumendil, A., Finel, H., Khvedelidze, I., Dietricht, S., Dreger, P., Hermine, O., Kyriakou, C., Robinson, S., Schmitz, N., Schouten, H. C., Tanase, A., & Montoto, S. (2020). Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-020-0929-y
Sureda A, et al. Changes in Patients Population and Characteristics of Hematopoietic Stem Cell Transplantation for Relapsed/refractory Hodgkin Lymphoma: an Analysis of the Lymphoma Working Party of the EBMT. Bone Marrow Transplant. 2020 May 15; PubMed PMID: 32415225.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. AU - Sureda,Anna, AU - Genadieva Stavrik,Sonja, AU - Boumendil,Ariane, AU - Finel,Hervé, AU - Khvedelidze,Irma, AU - Dietricht,Sascha, AU - Dreger,Peter, AU - Hermine,Olivier, AU - Kyriakou,Chara, AU - Robinson,Stephen, AU - Schmitz,Norbert, AU - Schouten,Harry C, AU - Tanase,Alina, AU - Montoto,Silvia, Y1 - 2020/05/15/ PY - 2019/11/21/received PY - 2020/04/27/accepted PY - 2020/04/09/revised PY - 2020/5/17/entrez JF - Bone marrow transplantation JO - Bone Marrow Transplant. N2 - Indications for autologous (auto-HCT) and allogeneic transplantation (allo-HCT) in relapsed/refractory Hodgkin lymphoma (rrHL) have been long established. The expectation is that long-term outcomes have significantly improved over time with increased experience in these procedures. The objective of this study was to assess whether this is the case and to identify further areas of improvement. A total of 13,639 adult patients receiving an auto-HCT or allo-HCT for rrHL were reported to the European Society for Blood and Marrow Transplantation (EBMT) over a 25-year period. Regarding auto-HCT, recipients are younger, interval between diagnosis and transplant shorter, peripheral blood has become the universal stem cell source and the use of total body irradiation is almost non-existent in recent years. Allo-HCT is currently mostly used as a second transplant; recipients are younger, fitter and less frequently, chemorefractory. Reduced intensity conditioning protocols have vastly replaced myeloablative protocols. Increasing numbers of haplo-HCT have been reported. Both in auto-HCT and allo-HCT, NRM, PFS and OS have significantly improved but relapse remains the main cause of treatment failure. A better selection of patients and improvements in the supportive care has resulted in a reduction in the NRM. Relapse after HCT remains unchanged and further research is needed. SN - 1476-5365 UR - https://www.unboundmedicine.com/medline/citation/32415225/Changes_in_patients_population_and_characteristics_of_hematopoietic_stem_cell_transplantation_for_relapsed/refractory_Hodgkin_lymphoma:_an_analysis_of_the_Lymphoma_Working_Party_of_the_EBMT L2 - http://dx.doi.org/10.1038/s41409-020-0929-y DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.